Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Merck
Colorcon
Harvard Business School
Baxter

Last Updated: May 20, 2022

INVELTYS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Inveltys patents expire, and what generic alternatives are available?

Inveltys is a drug marketed by Kala Pharms Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has seventy-eight patent family members in twelve countries.

The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

Summary for INVELTYS
International Patents:78
US Patents:10
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 53
Patent Applications: 5,254
Formulation / Manufacturing:see details
Drug Prices: Drug price information for INVELTYS
What excipients (inactive ingredients) are in INVELTYS?INVELTYS excipients list
DailyMed Link:INVELTYS at DailyMed
Drug patent expirations by year for INVELTYS
Drug Prices for INVELTYS

See drug prices for INVELTYS

Anatomical Therapeutic Chemical (ATC) Classes for INVELTYS

US Patents and Regulatory Information for INVELTYS

INVELTYS is protected by eleven US patents.

Patents protecting INVELTYS

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING OCULAR INFLAMMATION

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for INVELTYS

See the table below for patents covering INVELTYS around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2844295 NANOPARTICULES PHARMACEUTIQUES PERMETTANT UN TRANSPORT MUQUEUX AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) See Plans and Pricing
Brazil 112014027296 nanopartículas farmacêuticas mostrando transporte mucosal melhorado See Plans and Pricing
China 105916509 用于眼科应用和/或其它应用的组合物以及方法 (Compositions and methods for ophthalmic and/or other applications) See Plans and Pricing
Canada 2871748 NANOPARTICULES PHARMACEUTIQUES A TRANSPORT MUCOSAL AMELIORE (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2013166408 See Plans and Pricing
Japan 6816065 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Medtronic
Colorcon
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.